Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population

Genetics in Medicine

Volumn 19, Issue 5, 2017, Pages 529-536

  Wiesman, Chana ^a   Rose, Esther ^a   Grant, Allison ^a   Zimilover, Adam ^a   Klugman, Susan ^a   Schreiber Agus, Nicole ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ashkenazi Jewish; BRCA testing; group genetic counseling; hereditary cancer risk; population screening

Indexed keywords

ADULT; AGED; ARTICLE; ASHKENAZI JEW; FEMALE; FOUNDER EFFECT; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MALE; PILOT STUDY; TUMOR SUPPRESSOR GENE; UNITED STATES; EARLY CANCER DIAGNOSIS; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; HETEROZYGOTE DETECTION; JEW; MASS SCREENING; MIDDLE AGED; PROCEDURES;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; EARLY DETECTION OF CANCER; FEMALE; FOUNDER EFFECT; GENETIC CARRIER SCREENING; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HEALTH SURVEYS; HUMANS; JEWS; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; UNITED STATES;

EID: 85021700971     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.154     Document Type: Article

References (40)

1. Kauff ND, Perez-Segura P, Robson ME, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002;39:611-614.
2. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
3. Metcalfe KA, Poll A, Royer R, et al. A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. Br J Cancer 2013;109: 777-779.
4. Hirsh-Yechezkel G, Chetrit A, Lubin F, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol 2003;89:494-498.
5. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
6. Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269-275.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian, version 2.2016). 2016.
8. Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 2012;118:510-517.
9. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
10. Calzone KA, Biesecker BB. Genetic testing for cancer predisposition. Cancer Nurs 2002;25:15-25; quiz 26.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian, version 1.2015). 2015.
12. Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCArelated cancer in women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013;160:271-281.
13. Wang G, Beattie MS, Ponce NA, Phillips KA. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med 2011;13:1045-1050.
14. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:1091-1092.
15. Palomaki GE. Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics. Genet Med 2015;17:24-26.
16. Yurgelun MB, Hiller E, Garber JE. Population-wide screening for germline BRCA1 and BRCA2 mutations: too much of a good thing? J Clin Oncol 2015;33:3092-3095.
17. Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. Nat Rev Clin Oncol 2016;13: 41-54.
18. Richards CS, Ward PA, Roa BB, et al. Screening for 185delAG in the Ashkenazim. Am J Hum Genet 1997;60:1085-1098.
19. Plon SE. BRCA1/2 population screening: embracing the benefits. Curr Oncol 2015;22:e230-e231.
20. Rubinstein WS, Jiang H, Dellefave L, Rademaker AW. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genet Med 2009;11:629-639.
21. Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387-391.
22. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA 2014;111:14205-14210.
23. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 2015;107:dju379.
24. Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history based testing. J Natl Cancer Inst 2015;107:dju380.
25. Metcalfe KA, Eisen A, Lerner-Ellis J, Narod SA. Is it time to offer BRCA1 and BRCA2 testing to all Jewish women? Curr Oncol. 2015 Aug; 22(4): e233-e236.
26. Metcalfe KA, Mian N, Enmore M, et al. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 2012;133:735-740.
27. Prince AER. Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease. J Law Biosci 2015;2:365-395.
28. Radford C, Prince A, Lewis K, Pal T. Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. J Genet Couns 2014;23:522-530.
29. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
30. Ferreira JC, Schreiber-Agus N, Carter SM, Klugman S, Gregg AR, Gross SJ. Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze. Am J Obstet Gynecol 2014;211:197-204.
31. Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36082). 2015. https://www.cms.gov/medicare-coverage-database/details/icd-details.aspx?LCDid=3 6082&ver=20&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s =All&KeyWord=BRCA1&KeyWordLookUp=Title&KeyWordSearchType=And& id=135&bc=gAAAABAAAAAAAA%3d%3d&
32. Shao Y, Liu S, Grinzaid K. Evaluation of two-year Jewish genetic disease screening program in Atlanta: insight into community genetic screening approaches. J Community Genet 2015;6:137-145.
33. Delikurt T, Williamson GR, Anastasiadou V, Skirton H. A systematic review of factors that act as barriers to patient referral to genetic services. Eur J Hum Genet 2015;23:739-745.
34. Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat 2015;149:223-227.
35. Yablonski-Peretz T, Paluch-Shimon S, Gutman LS, et al. Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel. Breast Cancer Res Treat 2016;155:133-138.
36. Frey MK, Kim SH, Bassett RY, et al. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol 2015;139:211-215.
37. Cohen SA, Marvin ML, Riley BD, Vig HS, Rousseau JA, Gustafson SL. Identification of genetic counseling service delivery models in practice: a report from the NSGC Service Delivery Model Task Force. J Genet Couns 2013;22: 411-421.
38. Grinzaid KA, Page PZ, Denton JJ, Ginsberg J. Creation of a national, at-home model for Ashkenazi Jewish carrier screening. J Genet Couns 2015;24: 381-387.
39. Metcalfe K, Lubinski J, Lynch HT, et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010;102: 1874-1878.
40. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011;22 (suppl 1):i11-i17.